Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Vaxxa AB's Debt-to-EBITDA or its related term are showing as below:
FRA:7WA0'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.13 Med: -0.05 Max: 0.12
Current: -0.13
During the past 10 years, the highest Debt-to-EBITDA Ratio of Vaxxa AB was 0.12. The lowest was -0.13. And the median was -0.05.
FRA:7WA0's Debt-to-EBITDA is ranked worse than 100% of 1728
companies
in the Software industry
Industry Median: 1.03
vs FRA:7WA0: -0.13
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Vaxxa AB Debt-to-EBITDA Related Terms
Vaxxa AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Vaxxa AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7WA0 vs QH, SHOP, UBER: Debt-to-EBITDA Comparison
For the Software - Application subindustry, Vaxxa AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaxxa AB Debt-to-EBITDA vs Software Industry
For the Software industry and Technology sector, Vaxxa AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vaxxa AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Vaxxa AB (FRA:7WA0) has a Debt-to-EBITDA of 0.07 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vaxxa AB. According to the industry distribution chart, Vaxxa AB ranks #999999 out of 1728 companies in the Software industry.
Is Vaxxa AB's Debt-to-EBITDA too high?
Vaxxa AB's current Debt-to-EBITDA is 0.07. The Software industry median Debt-to-EBITDA is 1.03. Vaxxa AB's value of 0.07 is 93.2% below this industry median. Based on the distribution chart, Vaxxa AB ranks #999999 out of 1728 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Vaxxa AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Vaxxa AB's Debt-to-EBITDA compare to QH and SHOP?
According to the Software industry distribution chart, Vaxxa AB ranks #999999 out of 1728 companies for Debt-to-EBITDA. This places Vaxxa AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.03. Vaxxa AB's value of 0.07 is 93.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Software company?
The median Debt-to-EBITDA among Software companies is 1.03, based on 1,728 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaxxa AB's current Debt-to-EBITDA of 0.07 is 93.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vaxxa AB. For the Software industry, the median Debt-to-EBITDA is 1.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaxxa AB's current Debt-to-EBITDA is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxxa AB stock overvalued right now?
Vaxxa AB (FRA:7WA0) has a current Debt-to-EBITDA of 0.07. The stock's GF Value™ is €0.05, compared to a current price of €0.03 — trading 40% below its estimated fair value. The current Debt-to-EBITDA is 0.07 and 93.2% below the Software industry median of 1.03. Vaxxa AB's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Vaxxa AB (FRA:7WA0), the current Debt-to-EBITDA is 0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaxxa AB (FRA:7WA0) Overvalued in 2026?
Based on GuruFocus' analysis, Vaxxa AB stock appears to be undervalued.
The current stock price of €0.03 is trading 40% below its estimated GF Value™ of €0.05.
Key valuation signals for FRA:7WA0:
Debt-to-EBITDA: 0.07
GF Value™: €0.05 vs. price of €0.03 (40% below fair value)
Industry Position: 93.2% below the Software median (#999999 of 1728)
No single metric tells the full story. See the FRA:7WA0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaxxa AB is the auction site for those who want to buy and sell objects in vehicles, machinery, construction and industry. The company want to make it more accessible for both private individuals and companies to sell their objects with the motivation to pave the way for a more circular market. Vaxxa is Sweden's only auction platform where exactly the combination of auction broker and self-service is offered.
18GF Score
Get the complete analysis for FRA:7WA0
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7WA0 has been successfully added to your 
